H3 Biomedicine
Show Menu
About
About Us
Our Team
Our Story
An Eisai Company
Our Culture
Science
Scientific Approach
Pipeline
Scientific Publications
Partnering
Patients
Diseases We Study
Clinical Trials
Resources
Investigational Medication
Media Relations
Press Releases
In the News
Company Information
Careers
Opportunities
Benefits
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα WT and ERα MUT Breast Cancer
Seeking Additional Information?
Contact